Published in Eur J Surg Oncol on October 01, 1995
Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg (2006) 2.49
International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst (2010) 2.28
Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. Eur Radiol (2009) 1.21
Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer (2011) 1.15
The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review. Langenbecks Arch Surg (2014) 1.00
Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol (2005) 0.99
Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery (2012) 0.94
Percutaneous radiofrequency thermal ablation of primary and metastatic hepatic tumors: current concepts and review of the literature. Semin Intervent Radiol (2006) 0.83
Surgery for liver metastases from breast cancer. HPB (Oxford) (2006) 0.81
Radiofrequency ablation of metastatic lesions from breast cancer. J Ultrasound (2012) 0.78
Surgical management of breast cancer liver metastases. HPB (Oxford) (2011) 0.78
Patient selection for surgical management of primary and metastatic liver cancers: current perspectives. Semin Intervent Radiol (2006) 0.75
Complete pathologic response of HER2-positive breast cancer liver metastasis with dual anti-HER2 antagonism. BMC Cancer (2014) 0.75
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol (1996) 2.17
Prognostic importance of low c-erbB2 expression in breast tumors. J Natl Cancer Inst (1998) 2.00
Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience. Br J Cancer (1998) 1.96
Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol (2003) 1.96
Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg (1998) 1.79
Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol (2004) 1.79
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer (2001) 1.78
Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol (1989) 1.60
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol (2005) 1.54
High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol (1995) 1.36
Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer (1989) 1.35
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol (2007) 1.29
Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients. Arch Intern Med (1988) 1.25
The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer (2004) 1.22
Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res (1988) 1.16
Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy. Radiology (1987) 1.15
Compliance with cotrimoxazole prophylaxis for the prevention of opportunistic infections in HIV-positive tuberculosis patients in Thyolo district, Malawi. Int J Tuberc Lung Dis (2001) 1.07
Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol (1986) 1.05
Primary breast sarcoma: a review of 33 cases with immunohistochemistry and prognostic factors. Breast Cancer Res Treat (1989) 1.05
A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer (2006) 1.00
Conservative management of breast cancer. Br J Surg (1986) 1.00
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br J Cancer (1996) 0.99
Surgical and chemotherapeutic treatment of hepatic metastases from carcinoma of the breast. Surg Gynecol Obstet (1991) 0.98
p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol (2008) 0.98
Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer. Ann Oncol (2007) 0.97
Preoperative selective portal vein embolizations are an effective means of extending the indications of major hepatectomy in the normal and injured liver. Hepatogastroenterology (1998) 0.97
Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers. Oncogene (2000) 0.96
Long-term effect of internal mammary chain treatment. Results of a multivariate analysis of 1195 patients with operable breast cancer and positive axillary nodes. Radiother Oncol (1988) 0.96
Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol (1994) 0.96
Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol (2002) 0.95
[Neurosarcoma associated with Von Recklinghausen disease: apropos of 25 cases observed at the Gustave Roussy Institute from 1967 to 1990]. Bull Cancer (1992) 0.92
c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int J Cancer (1999) 0.92
Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'. Ann Oncol (2005) 0.90
Surgical approach to segment I for malignant tumors of the liver. Surg Gynecol Obstet (1992) 0.90
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. Ann Oncol (2012) 0.90
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol (1990) 0.89
Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann Oncol (2002) 0.89
A before-after study using OncoDoc, a guideline-based decision support-system on breast cancer management: impact upon physician prescribing behaviour. Stud Health Technol Inform (2001) 0.88
Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy. Ann Oncol (2008) 0.87
Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer (1994) 0.85
p53 protein overexpression and chemosensitivity in breast cancer. Institut Gustave-Roussy Breast Cancer Group. Lancet (1995) 0.85
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience. Eur J Cancer (1991) 0.85
Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer. Ann Oncol (2012) 0.83
Acute antiemetic efficacy and safety of dolasetron mesylate, a 5-HT3 antagonist, in cancer patients treated with cisplatin. European Dolasetron Study Group. Am J Clin Oncol (1994) 0.82
Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes. Ann Oncol (2001) 0.82
Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Cancer (1995) 0.82
Glucocorticoid receptor distribution in rat testis during postnatal development and effects of dexamethasone on immature peritubular cells in vitro. Andrologia (2000) 0.82
[Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status]. Bull Cancer (2009) 0.81
Microduplications encompassing the Sonic hedgehog limb enhancer ZRS are associated with Haas-type polysyndactyly and Laurin-Sandrow syndrome. Clin Genet (2014) 0.80
Quality of life after sentinel lymph node biopsy in early breast cancer. Eur J Surg Oncol (2004) 0.80
Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol (2003) 0.80
c-Ha-ras-1 polymorphism in human breast carcinomas: evidence for a normal distribution of alleles. Oncogene Res (1988) 0.80
Liver metastases from extremity soft tissue sarcoma. Am J Clin Oncol (1999) 0.80
Phase II study of elliptinium in advanced breast cancer. Cancer Treat Rep (1985) 0.80
[Alternating chemotherapy and hyperfractionated accelerated radiotherapy in non-metastatic inflammatory breast cancer]. Cancer Radiother (2000) 0.79
Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors. Breast Cancer Res Treat (1990) 0.79
[Gastric adenocarcinoma surgically treated. A multivariate analysis of prognostic factors]. Gastroenterol Clin Biol (1988) 0.79
Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: a preliminary report on safety. Semin Oncol (1996) 0.79
Circumferential pharyngolaryngectomy with total esophagectomy for locally advanced carcinomas. Ann Surg Oncol (1998) 0.79
Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma? J Immunother (1999) 0.78
Alternating radiotherapy and chemotherapy in non-metastatic inflammatory breast cancer. Int J Radiat Oncol Biol Phys (1990) 0.78
Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen. Ann Oncol (2002) 0.78
[Epidermoid cancer of the esophagus: is the combination of chemotherapy then surgery beneficial?]. Bull Cancer (1989) 0.78
Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer. Breast Cancer Res Treat (1990) 0.78
Surgical resection of pulmonary metastases. Up to what number? Am J Respir Crit Care Med (1994) 0.78
[Soft tissue sarcomas: general review]. Bull Cancer (1994) 0.78
Peritoneal carcinomatosis treatment with curative intent: the Institut Gustave-Roussy experience. Eur J Surg Oncol (1997) 0.78
[CA 15-3 and breast cancer]. Rev Med Interne (1994) 0.77
A phase I trial with recombinant interferon gamma (Roussel UCLAF) in advanced cancer patients. Cancer Immunol Immunother (1990) 0.77
Phase II study of elliptinium acetate salvage treatment of advanced breast cancer. Eur J Cancer (1993) 0.77
[Synchronous cancers of the esophagus and of the ORL area: results of combined treatments with esophagectomy (28 cases)]. Bull Cancer (1991) 0.77
Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. Eur J Cancer (1991) 0.77
Neoadjuvant chemotherapy in multiple synchronous head and neck and esophagus squamous cell carcinomas. Laryngoscope (1992) 0.77
[Esophageal pressure and serum gastrin after consumption of coffee]. Med Klin (1977) 0.76
[Upper limb lymphedema revealing breast cancer]. Rev Med Interne (2007) 0.76
Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen. Cancer (1988) 0.76
Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study. Ann Oncol (2009) 0.76
High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer. Br J Cancer (2011) 0.76
Frequency of symptomatic zinc deficiency in very low birth weight infants. Klin Padiatr (2012) 0.76
Antiemetic treatment with oral granisetron in patients receiving moderately emetogenic chemotherapy: a dose-ranging study. Clin Ther (1995) 0.75
Angiosarcoma of the breast after conservative surgery and radiation therapy for breast carcinoma: three new cases. Eur J Cancer (1996) 0.75
[Angiosarcoma of the breast. Apropos of 8 cases and review of the literature]. Bull Cancer (1997) 0.75
[Salvage chemotherapy in resistant malignant lymphomas (author's transl)]. Bull Cancer (1982) 0.75
Phase II study of high dose ifosfamide plus mesna in inoperable non small cell lung carcinoma. Eur J Cancer Clin Oncol (1988) 0.75
[Medical treatment of soft-tissue sarcomas in adults]. Bull Cancer (1985) 0.75
Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clin Breast Cancer (2001) 0.75
[Treatment of inflammatory cancer of the breast. Combined chemotherapy and radiotherapy. Apropos of 270 women treated at the Institut Gustave-Roussy]. Bull Cancer (1989) 0.75
[Treatment of advanced colonic and rectal adenocarcinoma: combination of 5-FU and high-dose folinic acid]. Bull Cancer (1983) 0.75
[Epidermoid cancer of the esophagus. Does the efficacy of chemoradiotherapy justify surgical abstention?]. Ann Chir (1989) 0.75
[Epidermoid cancers of the esophagus: combined chemotherapy, surgery and radiotherapy. Preliminary results in 50 cases]. Bull Cancer (1988) 0.75
[Treatment of hepatic metastases with unknown primary cancer]. Ann Gastroenterol Hepatol (Paris) (1985) 0.75
[Malignant lymphomas and other hematosarcomas with initial breast localization. Retrospective study of 20 cases]. Bull Cancer (1983) 0.75
[Chemotherapy by ambulatory continuous infusion using a portable pump: a feasibility trial]. Bull Cancer (1985) 0.75
[Combination vindesine, cyclophosphamide, cis-platinum and CCNU in esophageal epidermoid cancer. Preliminary analysis of 64 cases]. Bull Cancer (1985) 0.75
Hypothyroidism and goiter during interleukin-2 therapy. J Endocrinol Invest (1990) 0.75
[Initial chemotherapy in the treatment of inflammatory breast cancers. 230 cases]. Presse Med (1987) 0.75
Phase II study of pirarubicin in advanced non-small cell lung cancer. Eur J Cancer Clin Oncol (1989) 0.75
Phase II study of pirarubicin in advanced non-small cell lung cancer. Eur J Cancer Clin Oncol (1989) 0.75